Novo Nordisk’s obesity drug Wegovy was approved in China on Tuesday, though the company has not announced launch plans and starter doses in the U.S. have been in short supply for months.

Novo announced on Monday a $4.1 billion investment to build a U.S. facility to fill injection pens for Wegovy and Ozempic. Ozempic won approval from China in 2021, and Novo saw sales of the drug ...

Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk NOVO.B 3.06 % increase; green up pointing triangle to begin selling it in the world’s second ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt to help with their weight loss efforts. Ozempic is actually for type-2 ...

Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it against rival Eli Lilly, whose treatment, Zepbound, is yet to hit ...

China has approved Novo Nordisk A/S’s blockbuster Wegovy for chronic weight management, opening up competition for next-generation obesity drugs in the world’s second-largest economy.

Novo Nordisk gained approval in China for Ozempic as a diabetes treatment in 2021, where it has seen sales of the drug increase sharply to heights of 1.4 billion Danish Krone ($201 million) in the ...

Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world's second largest ...

Ozempic won approval from China in 2021, and Novo saw sales of the drug in the greater China region double to 4.8 billion Danish crowns ($698 million) last year.